000178400 001__ 178400
000178400 005__ 20240229143545.0
000178400 0247_ $$2doi$$a10.1158/0008-5472.CAN-21-3515
000178400 0247_ $$2pmid$$apmid:34983784
000178400 0247_ $$2ISSN$$a0008-5472
000178400 0247_ $$2ISSN$$a0099-7013
000178400 0247_ $$2ISSN$$a0099-7374
000178400 0247_ $$2ISSN$$a1538-7445
000178400 0247_ $$2altmetric$$aaltmetric:120207965
000178400 037__ $$aDKFZ-2022-00037
000178400 041__ $$aEnglish
000178400 082__ $$a610
000178400 1001_ $$0P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aAugustin, Hellmut$$b0$$eFirst author$$udkfz
000178400 245__ $$aAntiangiogenesis: Vessel Regression, Vessel Normalization, or Both?
000178400 260__ $$aPhiladelphia, Pa.$$bAACR$$c2022
000178400 3367_ $$2DRIVER$$aarticle
000178400 3367_ $$2DataCite$$aOutput Types/Journal article
000178400 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1641557957_3731
000178400 3367_ $$2BibTeX$$aARTICLE
000178400 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178400 3367_ $$00$$2EndNote$$aJournal Article
000178400 500__ $$aDKFZ-ZMBH Alliance / #EA:A190#
000178400 520__ $$aThe concepts of antiangiogenic tumor therapy were pioneered on the assumption that the inhibition of tumor angiogenesis should lead to the complete regression of the tumor-associated vasculature and thereby hold the tumor in an avascular dormant state. Yet, clinical trials revealed limited efficacy of angiogenesis inhibitors when used as monotherapy. Instead, antiangiogenic drugs proved effective to extend overall survival when used in combination with chemotherapy. This counterintuitive observation-inhibition of tumor vascularization should lead to less and not more delivery of chemotherapy to the tumor-led to the concepts of 'vessel normalization.' This refers to the notion that antiangiogenic drugs prune the most immature tumor vessels and spare mature vessels, thereby resulting in a more normal-appearing vasculature that leads to better access of chemotherapy to the tumor. The concepts of vessel normalization were first laid out in a landmark publication in Cancer Research in 2004. More than 600 studies on different aspects of vessel normalization have been published since then. Nevertheless, it is to this day less clear than ever to what extent vessel regression (leading to tumor starvation) and vessel normalization (facilitating chemotherapy) contribute to the clinical efficacy of antiangiogenic tumor therapy. This 'Landmark Commentary' puts the concepts of tumor vessel normalization in historical context and develops thereupon some of the most burning questions in the field of translational angiogenesis research that need to be answered to further advance the application of tumor vascular stroma reprogramming therapies.See related article by Tong and colleagues, Cancer Res 2004;64:3731-6.
000178400 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000178400 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178400 7001_ $$aKoh, Gou Young$$b1
000178400 773__ $$0PERI:(DE-600)2036785-5$$a10.1158/0008-5472.CAN-21-3515$$gVol. 82, no. 1, p. 15 - 17$$n1$$p15 - 17$$tCancer research$$v82$$x0008-5472$$y2022
000178400 909CO $$ooai:inrepo02.dkfz.de:178400$$pVDB
000178400 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000178400 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000178400 9141_ $$y2022
000178400 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000178400 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000178400 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000178400 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-12
000178400 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-12
000178400 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER RES : 2021$$d2022-11-12
000178400 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-12
000178400 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-12
000178400 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-12
000178400 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-12
000178400 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-12
000178400 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-12
000178400 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-12
000178400 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCANCER RES : 2021$$d2022-11-12
000178400 9200_ $$0I:(DE-He78)A190-20160331$$kA190$$lA190 Vaskuläre Onkologie und Metastasierung$$x0
000178400 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lA190 Vaskuläre Onkologie und Metastasierung$$x0
000178400 980__ $$ajournal
000178400 980__ $$aVDB
000178400 980__ $$aI:(DE-He78)A190-20160331
000178400 980__ $$aUNRESTRICTED